D1DR and D2DR antagonists-induced antinociception could be alleviated by D1DR, D2DR, and D1/D2DR heteromer agonists, which indicated that D1DR and D2DR antagonists attenuate TCI-induced bone cancer through inhibiting D1/D2DR heteromers. Here, DRD2 is linked to bone cancer.